- Reframe Daily
- Posts
- Reframe Daily: Heart Pill Reverses Damage, New Colon-Cancer “Smart Bomb,” Pig-Organ Clue & Mor
Reframe Daily: Heart Pill Reverses Damage, New Colon-Cancer “Smart Bomb,” Pig-Organ Clue & Mor
A well-known pill easing heart strain, an antibody-drug conjugate tackling late-stage colon cancer, insight that may make pig organs safe for people, a gene switch that stalls arthritis, and an mRNA HIV vaccine that sparks the right antibodies—all discovered today.
Christin Chong, PhD
July 30, 2025
Reframe Daily is where Christin Chong (neuroscience PhD, chaplain, healthtech strategy consultant) curates optimistic and credible healthtech news so you don’t have to.
Today in one sentence: Scientists found that a common heart-failure pill softened thickened hearts, a new “smart-bomb” drug shrank stubborn colon tumors, a pig-liver transplant study mapped the immune attack that blocks organ swaps, flipping one gene slowed arthritis in mice, and an mRNA HIV vaccine finally made the hard-to-get antibodies doctors need.
Christin’s note: Reframe Daily is curated based on current Reframe discord community chatter topics! If you’d like to shape Reframe Daily to your interests, you are welcomed to join the reframe community here → https://forms.gle/tN3oabFTsDF21VnS8
Good news: A long-used heart-failure pill (sacubitril/valsartan) made thick, stiff hearts softer in a phase-2 study, so people with high blood pressure might avoid heart failure.
Market readiness: 😊😊😊 (already sold for heart failure; now in mid-stage testing for this brand-new purpose)
Good news: A brand-new “smart-bomb” drug, precemtabart tocentecan, shrank tough colon tumors in its very first human study, giving new hope when current treatments fail.
Market readiness: 😊😊 (early safety/efficacy data; needs larger phase 2/3 studies)
Good news: Doctors mapped which human immune cells attack a transplanted pig liver, knowledge that could help design safer donor pigs and ease the organ shortage one day.
Market readiness: 😊 (proof-of-concept in a brain-dead donor; many hurdles before living-patient use)
Good news: Switching a single gene called NFIA in cartilage slowed arthritis damage in mice, hinting at future medicines to protect aching knees and hips.
Market readiness: 😊 (lab and animal work only; drug discovery still ahead)
Good news: An experimental mRNA HIV vaccine made the hard-to-produce “tier-2” antibodies scientists have chased for decades, a hopeful step toward a shot that prevents HIV.
Market readiness: 😊😊 (first-in-human immune study; still needs large efficacy trials)
Thank you for taking the time to take care of yourself and your loved ones.